These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 23977979)
1. The effect of severity of depressive disorder on economic burden in a university hospital in Singapore. Ho RC; Mak KK; Chua AN; Ho CS; Mak A Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):549-59. PubMed ID: 23977979 [TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression. Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952 [TBL] [Abstract][Full Text] [Related]
3. Depression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatment. Revicki DA; Simon GE; Chan K; Katon W; Heiligenstein J J Fam Pract; 1998 Dec; 47(6):446-52. PubMed ID: 9866670 [TBL] [Abstract][Full Text] [Related]
4. Cost of multiple sclerosis in the Czech Republic: the COMS study. Blahova Dusankova J; Kalincik T; Dolezal T; Kobelt G; Havrdova E Mult Scler; 2012 May; 18(5):662-8. PubMed ID: 21965424 [TBL] [Abstract][Full Text] [Related]
5. Costs associated with attempted suicide among individuals with bipolar disorder. Stensland MD; Zhu B; Ascher-Svanum H; Ball DE J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595 [TBL] [Abstract][Full Text] [Related]
6. Cost-of-illness study of patients subjected to cardiac rhythm management devices implantation: results from a single tertiary centre. Fanourgiakis J; Simantirakis E; Maniadakis N; Kourlaba G; Kanoupakis E; Chrysostomakis S; Vardas P Europace; 2013 Mar; 15(3):366-75. PubMed ID: 23148117 [TBL] [Abstract][Full Text] [Related]
7. Economic burden of schizophrenia: empirical analyses from a survey in Thailand. Phanthunane P; Whiteford H; Vos T; Bertram M J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090 [TBL] [Abstract][Full Text] [Related]
8. The economic burden of depression in Sweden from 1997 to 2005. Sobocki P; Lekander I; Borgström F; Ström O; Runeson B Eur Psychiatry; 2007 Apr; 22(3):146-52. PubMed ID: 17194573 [TBL] [Abstract][Full Text] [Related]
9. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Sobocki P; Ekman M; Agren H; Runeson B; Jönsson B Int J Clin Pract; 2006 Jul; 60(7):791-8. PubMed ID: 16846399 [TBL] [Abstract][Full Text] [Related]
10. [Long-term health insurance payments for depression in Germany - a secondary analysis of routine data]. Stamm K; Reinhard I; Salize HJ Neuropsychiatr; 2010; 24(2):99-107. PubMed ID: 20605005 [TBL] [Abstract][Full Text] [Related]
11. The economic impact of depression: resistance or severity? Fostick L; Silberman A; Beckman M; Spivak B; Amital D Eur Neuropsychopharmacol; 2010 Oct; 20(10):671-5. PubMed ID: 20624674 [TBL] [Abstract][Full Text] [Related]
12. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Birnbaum HG; Kessler RC; Kelley D; Ben-Hamadi R; Joish VN; Greenberg PE Depress Anxiety; 2010; 27(1):78-89. PubMed ID: 19569060 [TBL] [Abstract][Full Text] [Related]
13. Economic burden of obesity in primary total knee arthroplasty. Dowsey MM; Liew D; Choong PF Arthritis Care Res (Hoboken); 2011 Oct; 63(10):1375-81. PubMed ID: 21793232 [TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of short-term psychodynamic psychotherapy and solution-focused therapy in the treatment of depressive and anxiety disorders during a one-year follow-up. Maljanen T; Paltta P; Harkanen T; Virtala E; Lindfors O; Laaksonen MA; Knekt P; J Ment Health Policy Econ; 2012 Mar; 15(1):13-23. PubMed ID: 22611089 [TBL] [Abstract][Full Text] [Related]
15. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. Li X; Gignac MA; Anis AH Med Care; 2006 Apr; 44(4):304-10. PubMed ID: 16565630 [TBL] [Abstract][Full Text] [Related]
16. Health and disability costs of depressive illness in a major U.S. corporation. Druss BG; Rosenheck RA; Sledge WH Am J Psychiatry; 2000 Aug; 157(8):1274-8. PubMed ID: 10910790 [TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic considerations when evaluating treatment options for major depressive disorder. Burke MJ; Silkey B; Preskorn SH J Clin Psychiatry; 1994 Sep; 55 Suppl A():42-52; discussion 53-4, 98-100. PubMed ID: 7961542 [TBL] [Abstract][Full Text] [Related]
18. High vitamin B12 level and good treatment outcome may be associated in major depressive disorder. Hintikka J; Tolmunen T; Tanskanen A; Viinamäki H BMC Psychiatry; 2003 Dec; 3():17. PubMed ID: 14641930 [TBL] [Abstract][Full Text] [Related]
19. The costs of depression: direct and indirect; treatment versus nontreatment. Panzarino PJ J Clin Psychiatry; 1998; 59 Suppl 20():11-4. PubMed ID: 9881536 [TBL] [Abstract][Full Text] [Related]
20. Costs and quality of life of multiple sclerosis in Austria. Kobelt G; Berg J; Lindgren P; Plesnilla C; Baumhackl U; Berger T; Kolleger H; Vass K Eur J Health Econ; 2006 Sep; 7 Suppl 2():S14-23. PubMed ID: 17310339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]